Three Purities

Biodata

Feature	Value
Name	Three Purities
Alias(es)	Sanqing; Three Purities Group
Original Name	三清
Type	Pharmaceutical and medical-technology company
Headquarters	Sanqing Garden, including the Pangu Research Institute 199 200
Leadership	Wei Kang — President/CEO 206 552
Major Divisions	Pharmaceutical R&D, AI Pharmaceutical Laboratory, Medical Device Division, Sanqing Beauty, Dragon Map Division, Charity Foundation 380
Status	Active
First Appearance	10

Background / History

Three Purities began as a small pharmaceutical company whose limited R&D capacity was openly questioned by industry rivals. Its early growth was driven by its anticancer drug and the commercialization of its formulas. 10 29 31

After its initial success, the company acquired land around its original site and planned a major headquarters complex benchmarked against Apple’s “spaceship” headquarters. Local authorities welcomed the expansion because of its anticipated economic impact and employment opportunities. 53

The company expanded from pharmaceuticals into beauty products, generic drugs, health supplements, medical devices, gene therapy, agricultural technology, and medical data services. By the time of its first annual report, Sanqing Group reported revenue exceeding US$40 billion; it later reached US$100.1 billion in annual revenue and was described as the global pharmaceutical leader. 116 158 290 552

Major Arcs

Arc	Chapters	Key developments
Early commercialization	31, 53	Three Purities faces attempted manipulation during negotiations over its whitening-drug formula, then begins purchasing land for a large-scale headquarters and production expansion. 31 53
Beauty division expansion	69–70	Sanqing Beauty broadens its planned skincare, makeup, anti-aging, and haircare lines. Sheng Changya becomes its president and receives 5% equity. 69 70
Alzheimer’s drug controversy	89–101	Following Fox News allegations of technology theft, Three Purities suspends overseas trials and launches, releases its clinical data, and ultimately establishes an overseas branch after its Alzheimer’s drug demonstrates decisive efficacy. 89 91 98
Entry into generic drugs	116	The company launches China’s first generic Glatiramer drug, alarming established generic-drug manufacturers. 116
Research-institute expansion	157–158	Three Purities’ laboratories attract graduate students and PhDs; the company establishes the Pangu Research Institute and seeks university partnerships. 157 158
Rare-disease and gene-therapy push	176–185, 257	Three Purities develops medical big-data infrastructure for rare-disease patients, enters gene therapy, and advances a Thalassemia Gene Drug through Phase III trials. 176 180 257
Patent war	259–270	The company faces patent pressure over gene-editing technology, counters with its fourth-generation gene-editing technology, and sees the Broad Institute withdraw its lawsuit. 259 270
Medical-device expansion	423–539	Three Purities develops portable medical devices, endoscopic systems, capsule gastroscopy, ultrasonic scalpels, and artificial blood vessels. 423 435 502 539
Global corporate prominence	290–292, 552	Sanqing enters the Fortune Global 500 at approximately 276th place, while Wei Kang gains the title “Medicine King.” The company later reports US$100.1 billion in annual revenue. 290 292 552
Education and talent cultivation	553–554	Three Purities supports employee education and funds the establishment of Gusu University Sanqing Campus in Kunshi City. 553 554

Operations

Pharmaceutical Research

Three Purities develops original drugs, generic drugs, over-the-counter drugs, health supplements, and gene therapies. Its strategic goal is to establish major products across medical fields rather than rely solely on oncology and neurodegenerative-disease drugs. 117 118

• Develops drugs for cancer, Alzheimer’s disease, rare diseases, pain management, cardiovascular conditions, allergies, obesity, and other conditions. 10 91 120 127 132 211 241
• Operates dedicated Oncology, Neuroscience, Biology, Generic Drugs, and AI Pharmaceutical laboratories. 157 380
• Uses an AI Pharmaceutical System to accelerate data collection, analysis, algorithm construction, and drug development. 161 166
• Acquires and reviews discarded formulas as a source of potentially valuable side effects and new research directions. 117 211 299

Gene Therapy

Three Purities pursues gene therapies for rare diseases and possesses fourth-generation gene-editing technology. 176 257 270

• Its Thalassemia Gene Drug achieved near-perfect Phase III results, with more than 1,000 total trial participants across all phases in China and Eagle Country. 257
• The company obtained a commercial patent license from the University of California team for CRISPR gene-editing technology. 257
• It later defeated the Broad Institute’s patent challenge after launching its own fourth-generation gene-editing technology. 270

Medical Devices

The Medical Device Division is led by Lu Tingfeng. 380

• Develops portable medical equipment, including magnetic-control capsule gastroscopy systems. 435
• Produces endoscope systems integrating an ultrasound probe, high-definition camera, and miniature ultrasonic scalpel. 502
• Develops artificial blood vessels in large-, medium-, and small-caliber specifications; its small-caliber vessels are described as a world first. 539
• Cooperates with the China Steel Research Institute on magnetostrictive material for ultrasonic scalpels, with potential military and aerospace uses. 486

Sanqing Beauty

Sanqing Beauty is the group’s beauty and consumer-health division, led by Sheng Changya. 70 380

• Expands into skincare, cosmetics, anti-aging products, haircare, and health supplements. 69 125
• Its Hair Growth Serum became a global sensation and received rapid FDA approval before entering overseas markets. 107
• Markets health supplements using xianxia-inspired branding, including Dragon Power Pill, Marrow Cleansing Pill, and Foundation Establishment Pill. 125 126
• Developed a Super Moisturizing Factor from a drug side effect; its Moisturizing Essence later gained attention for unconventional uses. 117 153

Dragon Map

Dragon Map, also called Longtu, is Three Purities’ medical big-data platform and is led by Xiang Gaofei. 176 180 380

• Provides medical information and electronic medical records. 180 199
• Was designed to connect rare-disease patients nationwide and incorporate them into medical big data. 176 180
• Supports access to later services, including Tianyan 1.0 through the Dragon Map app. 543

Selected Products and Technologies

Product / Technology	Field	Documented significance
Anticancer Drug	Oncology	The drug establishes Three Purities’ early reputation as a developer of “miracle” medicines. 10
AD Special Effect Drug	Neuroscience	Demonstrates efficacy that surpasses Biogen’s competing Alzheimer’s drug, with markedly fewer side effects. 91
Hair Growth Serum	Beauty / Haircare	Becomes globally popular after helping Bull Country’s First Prince regrow his hair; later receives FDA approval. 107
Super Hemostatic Agent	Emergency medicine	Stops bleeding within three seconds and is considered useful in emergency and military contexts. 120 240
Three Purities Painkiller	Pain management	A non-addictive painkiller positioned as a potential replacement for opioid painkillers. 132 137
Generic Glatiramer Drug	Generic drugs	China’s first generic version; rivals consider its quality comparable to the original drug. 116
Thalassemia Gene Drug	Gene therapy	Achieves highly successful Phase III results and advances toward launch in China and Eagle Country. 257
Neural Regeneration Factor	Neuroscience	Cures a nine-year vegetative patient and draws global attention. 335
Capsule Gastroscopy	Medical devices	Offers a less invasive gastroscopy method through a magnetic-control capsule system. 435
Artificial Blood Vessels	Medical devices	Includes small-caliber vessels that fill a domestic and international research gap. 539

Research and Facilities

Pangu Research Institute

The Pangu Research Institute is Three Purities’ principal research center, named after the Chinese creator god Pangu. It focuses on biology, chemistry, and pharmaceuticals while operating a postdoctoral workstation for high-level young researchers. 158

• Seeks to cultivate pioneering scientific talent and support innovative research. 158
• Cooperates with Jingda University’s State Key Laboratory of Protein and Plant Gene Research and State Key Laboratory of Natural Medicines and Biomimetic Drugs. 158
• Receives interest from the State Key Laboratory of Pharmaceutical Biotechnology at Nanda. 158
• Forms part of Sanqing Garden’s headquarters complex. 199 200

Sanqing Garden

Sanqing Garden is the company’s headquarters campus and a public attraction with limited daily visit tickets. 199 200

• Includes employee dormitories, cafeterias, a gym, gardens, animals, and low-density office areas. 199 200
• Features molecular-formula sculptures, DNA double-helix fountain designs, capsule-shaped meeting rooms, and Pangu Square. 200
• Its popularity contributes to local tourism, including riverboat tours for visitors unable to obtain entry tickets. 200

Corporate Policies

• Research orientation — Three Purities publicly states that it will develop medicines benefiting society regardless of short-term profit or immediate success. 76
• Affordability — The company’s researchers argue that a drug “loses its reason for existing” if patients cannot afford it. 165
• Domestic prioritization — Three Purities has suspended overseas access to certain drugs during disputes and has retained strategic drugs for domestic use. 89 334 335
• Employee support — The company offers relatively stable work arrangements, food and housing for single employees, overtime pay, high bonuses, and interest-free housing loans after three years of employment. 157
• Talent cultivation — Wei Kang attributes the company’s success to talent and innovation, emphasizing the creation of an environment that develops ordinary people into capable professionals. 552
• Charity — Three Purities raised 5 billion yuan for Thalassemia drug development and clinical trials, providing free treatment to severely ill children. 247

Relationships

• Wei Kang — President and chief decision-maker; directs expansion into pharmaceuticals, gene therapy, medical devices, research institutes, and overseas markets. 98 158 206 552
• Chen Yiqing — Director of the Neuroscience Laboratory; leads major neuroscience projects and contributes to the Alzheimer’s drug program. 76 89 380
• Wenren Long — Director of the AI Pharmaceutical Laboratory; oversees AI and pharmaceutical-chemistry work. 157 214 380
• Tang Que — Director of the Biology Laboratory; associated with rare-disease and gene-therapy research. 165 380
• Gu Xian — Director of the Generic Drugs Laboratory. 150 380
• Lu Tingfeng — President of the Medical Device Division. 380 502
• Sheng Changya — President of Sanqing Beauty and head of the Charity Foundation. 70 278 380
• Xiang Gaofei — President of the Dragon Map Division. 109 380
• Jingda University — Academic partner supporting the Pangu Research Institute and postdoctoral recruitment. 158
• Pfizer — Competitor and occasional prospective partner; its representatives initially seek cooperation on the Alzheimer’s drug, while later discussions concern gene-drug cooperation. 89 270
• Broad Institute — Patent-war opponent in the dispute over gene-editing technology; later withdraws its lawsuit against Three Purities. 259 270

Notable Quotes

“The innocent will prove themselves innocent. Please believe in Three Purities. We have always been committed to relieving the suffering of all humanity.” 89

“If no one can afford to use a drug, then it loses its reason for existing.” 165